NCT02667496View on ClinicalTrials.gov

Safety Study of Sargramostim in Treating Patients With Mild Cognitive Impairment Due to Alzheimer's Disease

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 30, 2016

Primary Completion Date

March 31, 2017

Study Completion Date

March 31, 2017

Conditions
Dementia Alzheimer's Type
Interventions
DRUG

Sargramostim GZ402664

Pharmaceutical form:solution Route of administration: subcutaneous

DRUG

Placebo

Pharmaceutical form:solution Route of administration: subcutaneous

DRUG

Florbetapir F18

Pharmaceutical form:solution Route of administration: intravenous

Trial Locations (1)

77030

Investigational Site Number 840001, Houston

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

lead

Sanofi

INDUSTRY

NCT02667496 - Safety Study of Sargramostim in Treating Patients With Mild Cognitive Impairment Due to Alzheimer's Disease | Biotech Hunter | Biotech Hunter